Editorial Board Members’ Collection Series: Chitosan in Biomedicine: Current Status, Future Perspectives and Challenges

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".

Deadline for manuscript submissions: 30 September 2024 | Viewed by 889

Special Issue Editors

Guest Editor
Nanobiofar Group (GI-1643), Department of Pharmacology, Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Santiago de Compostela-Campus Vida, 15782 Santiago de Compostela, Spain
Interests: biomaterials; new drug delivery systems; gene therapy; nanomedicine; micro-nanotechnologies; pulmonary delivery

E-Mail Website
Guest Editor
Department of Drug Sciences, University of Pavia, Viale Taramelli 12, 27100 Pavia, Italy
Interests: amphiphilic polymers; bioactive polysaccharides; nanoemulsions; poorly soluble drug formulations; nanoparticles; theranostics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In recent decades, chitosan biomaterial, mainly in its nanostructure form, has gained extraordinary relevance in the biomedical field due to its unique biological properties. It is nontoxic, biodegradable, biocompatible, mucoadhesive and promotes mucosal drug absorption. In addition, it has antibacterial, antimicrobial, anti-inflammatory, antitumor, immunostimulatory and wound healing properties. For all these reasons, chitosan and its derivatives are having an enormous impact on the fields of drug delivery, gene therapy, vaccination, tissue engineering, regenerative medicine and wound dressing, among others. In their application, the use of chitosan-based starting materials that are well characterized is an urgent requirement, and the properties of chitosan derivatives are being continuously improved to ensure they are suitable for application.

This Special Issue focuses on the latest research advances on systems based on chitosan and its derivatives in biomedicine, including (but not limited to): (a) delivery of proteins, antibiotics, antigens and nucleic acids; (b) diagnosis and treatment of cancer (theranostics); and (c) applications in tissue engineering. The aim is to provide an updated status and perspectives on future research in the aforementioned topics and to emphasize the challenges for their translation to the clinic.

Original research articles and review manuscripts on the aforementioned topics are welcome.

Prof. Dr. Carmen Remuñán-López
Prof. Dr. Maria Bonferoni
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • biomedicine
  • cancer
  • chitosan
  • drug delivery
  • gene therapy
  • nanostructure
  • tissue engineering
  • vaccine
  • nanotechnology
  • theranostics

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


16 pages, 4439 KiB  
Fabrication of Ciprofloxacin-Loaded Sodium Alginate Nanobeads Coated with Thiol-Anchored Chitosan Using B-390 Encapsulator Following Optimization by DoE
by Mahwash Mukhtar, Ildikó Csóka, Josipa Martinović, Gordana Šelo, Ana Bucić-Kojić, László Orosz, Dóra Paróczai, Katalin Burian and Rita Ambrus
Pharmaceutics 2024, 16(6), 691; https://doi.org/10.3390/pharmaceutics16060691 - 21 May 2024
Viewed by 516
Most infectious diseases of the gastrointestinal tract can easily be treated by exploiting the already available antibiotics with the change in administration approach and delivery system. Ciprofloxacin (CIP) is used as a drug of choice for many bacterial infections; however, long-term therapy and [...] Read more.
Most infectious diseases of the gastrointestinal tract can easily be treated by exploiting the already available antibiotics with the change in administration approach and delivery system. Ciprofloxacin (CIP) is used as a drug of choice for many bacterial infections; however, long-term therapy and off-site drug accumulation lead to an increased risk of tendinitis and peripheral neuropathy. To overcome this issue, nanotechnology is being exploited to encapsulate antibiotics within polymeric structures, which not only facilitates dose maintenance at the infection site but also limits off-site side effects. Here, sodium alginate (SA) and thiol-anchored chitosan (TC) were used to encapsulate CIP via a calcium chloride (CaCl2) cross-linker. For this purpose, the B-390 encapsulator was employed in the preparation of nanobeads using a simple technique. The hydrogel-like sample was then freeze-dried, using trehalose or mannitol as a lyoprotectant, to obtain a fine dry powder. Design of Experiment (DoE) was utilized to optimize the nanobead production, in which the influence of different independent variables was studied for their outcome on the polydispersity index (PDI), particle size, zeta potential, and percentage encapsulation efficiency (% EE). In vitro dissolution studies were performed in simulated saliva fluid, simulated gastric fluid, and simulated intestinal fluid. Antibacterial and anti-inflammatory studies were also performed along with cytotoxicity profiling. By and large, the study presented positive outcomes, proving the advantage of using nanotechnology in fabricating new delivery approaches using already available antibiotics. Full article
Show Figures

Figure 1

Back to TopTop